Trial of SAGE-217 in Patients with Major Depressive Disorder | Zendy

Handan Gunduz-Bruce | Zendy; Christopher Silber | Zendy; Inder Kaul | Zendy; Anthony J. Rothschild | Zendy; Robert Riesenberg | Zendy; Abdul J. Sankoh | Zendy; Haihong Li | Zendy; Robert Lasser | Zendy; Charles F. Zorumski | Zendy; David R. Rubinow | Zendy; Steven M. Paul | Zendy; Jeffrey M. Jonas | Zendy; James Doherty | Zendy; Stephen Kanes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of SAGE-217 in Patients with Major Depressive Disorder

Author(s) -

Handan Gunduz-Bruce,

Christopher Silber,

Inder Kaul,

Anthony J. Rothschild,

Robert Riesenberg,

Abdul J. Sankoh,

Haihong Li,

Robert Lasser,

Charles F. Zorumski,

David R. Rubinow,

Steven M. Paul,

Jeffrey M. Jonas,

James Doherty,

Stephen Kanes

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1815981

Subject(s) - clinical global impression , placebo , medicine , depression (economics) , sage , randomization , major depressive disorder , anxiety , hamilton rating scale for depression , randomized controlled trial , psychiatry , pathology , physics , nuclear physics , economics , macroeconomics , alternative medicine , amygdala

Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research